NHS 为严重脱发患者引入 ritlecitinib，在 24 周内使 25% 的患者受益。 NHS introduces ritlecitinib for severe alopecia patients, benefiting 25% within 24 weeks.

美国国家卫生服务局正在推出ritlecitinib,这是一种针对12岁及以上严重脱发患者的新药,可在24周内显著减少脱发并改善约25%的患者的头发再生. The NHS is introducing ritlecitinib, a new drug for severe alopecia patients aged 12 and older, which can significantly reduce hair loss and improve regrowth in about 25% of users within 24 weeks. 艾伦·格林 （Alan Green） 认为这种药物本可以挽救他的继女艾丽西亚·皮利普祖克 （Alicia Pylypczuk），她是一名前急诊医生，她与与病情相关的抑郁症作斗争，并在 2020 年不幸结束了自己的生命。 Alan Green believes the drug could have saved his stepdaughter, Alicia Pylypczuk, a former A&E doctor who struggled with depression linked to her condition and tragically took her life in 2020. 这种治疗为受脱发影响的人带来了希望。 The treatment offers hope for those affected by alopecia.